Favorable Outcome in Infants Hospitalized With COVID-19: Single Center Experience from Athens, Greece

This study aims to describe the clinical characteristics and outcome of 92 infants (aged <12 months) with community-acquired coronavirus disease 2019 (COVID-19) between March, 2020 and June, 2021 at a single center in Athens. Infants with COVID-19 developed mild disease (89, 96.7%), and were infected mostly by their household contacts (74, 80.4%). Disease complications were rare, indicating that hospitalization is the result of low threshold for admission rather than disease severity.

Keywords: Community-acquired, Outcome, Hospitalization, Management, Severity.

Published online: June 11, 2022; PI: S097475591600434

Children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), typically have a milder and often asymptomatic course of illness [1]. Severe disease is rare and mortality is associated with existing comorbidities or disease complications such as the multisystem inflammatory syndrome (MIS-C) [2]. Coronavirus disease 2019 (COVID-19) in infants was a major concern when the disease was first described, in view of their immunological immaturity and close contact with household members infected with SARS-CoV-2 [2]. Reports indicate that 62% of children hospitalized with COVID-19 are <1 year of age, although it is not clear if this is related to disease severity or to a lower threshold for admission [3,4].

There are limited data on disease severity in infants with community-acquired COVID-19 and these largely come from case reports and small case series. The primary aim of this study was to describe disease characteristics, transmission and outcome of COVID-19 in infants. The secondary aim was to identify clinical or laboratory markers linked to disease severity.

This single-center medical record review was conducted for the period between March, 2020 and June, 2021 in infants (aged <12 months) admitted to a COVID-19 referral pediatric hospital in Athens, Greece, following a positive reverse transcriptase-polymerase chain reaction (RT-PCR) for SARS-CoV-2. After clearance from the Institutional ethics committee, medical records of infants included in the study were reviewed for demographic, clinical and laboratory characteristics, and disease outcomes. Amplification cycle threshold (Ct) values were recorded, with lower values indicating a higher viral load. Ct cutoff for negativity was 35-40 cycles [5]. Contact tracing was performed by standard interview of parents for suspected COVID-19 symptoms, and reason and timing of PCR testing in any family member. The severity of COVID-19 was defined as asymptomatic, mild, moderate, severe and critical, according to the National Institutes of Health (NIH) classification [6].

Statistical analysis was performed using SPSS, version 25.0. Associations between infants’ characteristics were evaluated with spearman’s Rho correlation coefficient. P-value <0.05 was considered as statistical significant.

Overall, 92 previously healthy infants (56.5% boys) with mean (SD) age of 3.3 (3.1) months were admitted during the study period. Demographic and clinical characteristics of these infants are shown in Table 1. The majority of the infants (89, 96.7%) had a mild illness. Three patients required supplemental oxygen administration, while only one developed moderate respiratory distress and required pediatric intensive care unit (PICU) admission for short course non-invasive ventilation.

Table 1 Characteristics of Infants With COVID-19 in Athens, Greece (2020-21) (N=92)

| Characteristics                        | N   | %   |
|----------------------------------------|-----|-----|
| Age at admission (mo)                  | 3.3 | 3.1 |
| Girls                                  | 40  | 43.5|
| History of COVID-19 exposure           | 74  | 80.4|
| Household COVID-19 case                | 74  | 100 |
| Ct value                               | 16.7| 5.3 |

Symptoms and clinical findings

| Symptoms                          | N   | %   |
|-----------------------------------|-----|-----|
| Fever (>38°C)                     | 62  | 67.4|
| Low-grade fever (<38°C)           | 33  | 35.9|
| Cough                             | 20  | 21.7|
| Rhinitis                          | 43  | 46.7|
| Poor feeding                      | 38  | 41.3|
| Gastrointestinal (vomiting, diarrhea) | 25  | 27.2|
| Respiratory distress              | 3   | 3.3 |
| Febrile seizures                  | 1   | 1.1 |

Laboratory findings

| Laboratory findings               | N   | %   |
|-----------------------------------|-----|-----|
| White blood cells (x10³/µL)       | 9429| 4139|
| Neutrophil count (x10³/µL)        | 3088| 2280|
| Lymphocyte count (x10³/µL)        | 4862| 2527|
| Neutrophil/Lymphocyte count       | 0.9 | 0.9 |
| C-reactive protein (CRP) (mg/L)   | 7.9 | 32.4|
| Platelet count (x10³/µL)          | 373196| 127003|
| Creatinine (mg/dL)                | 0.3 | 0.1 |
| Alanine aminotransferase (ALT) (U/L) | 30.8| 27.6|
| Aspartate aminotransferase (AST) (U/L) | 47.9| 26.9|
| Abnormal chest radiograph         | 3   | 3.3 |

Disease severity

| Disease severity | N   | %   |
|------------------|-----|-----|
| Mild             | 89  | 96.7|
| Severe           | 3   | 3.3 |

Treatment

| Treatment          | N   | %   |
|--------------------|-----|-----|
| Antimicrobials     | 22  | 24.2|
| Corticosteroids    | 3   | 3.3 |
| Remdesivir         | 3   | 2.2 |
| Supplemental oxygen| 3  | 3.3 |
| Non-invasive ventilation | 1 | 1.1 |
| No respiratory support | 89 | 96.7|

Outcome

| Outcome                     | N   | %   |
|-----------------------------|-----|-----|
| Co-infection                | 2   | 2.2 |
| Hospital stay (d)           | 4.1 | 1.9 |
| Pediatric intensive care unit (PICU) admission | 1 | 1.1 |

Values in no. (%) or mean (SD); a<24 (26.1%) had neutropenia; bNone had moderate or clinical disease; cNo infant required invasive ventilation; dNo infant developed any complications or died.
Mean (SD) Ct value was 16.7 (5.3), indicating high viral load. Two infants were diagnosed with concomitant bacterial infection on admission (one with urinary tract infection and one with gastroenteritis caused by Campylobacter spp). Antimicrobials were administered in 22 (24.2%) of the infants and the majority of them (18, 81.2%) were infants <3 months old that were initially admitted with fever with no focus. Antibiotics were given in these, pending culture results, with a median treatment duration of 3 days. Mean (SD) duration of hospitalization was 4.1 (1.9) days, and all infants had a favorable clinical outcome without complications. No infant to adult transmission was reported during hospitalization or during follow-up.

Results from a multivariate analysis identifying risk factors related to disease severity showed that higher Ct values (hence lower viral loads) were seen in older infants ($P=0.01$), and were associated with higher white blood cell (WBC) ($P=0.04$) and neutrophil count ($P=0.3$), as well as increased C-reactive protein (CRP) ($P=0.005$). There was no significant association between patient’s age and days of hospitalization, and between Ct values and laboratory results with the duration of hospitalization.

There is now growing evidence that children, especially infants and toddlers, develop mostly asymptomatic or mild COVID-19 [1]. This may be due to the immunological characteristics of this age group, the physiology of their respiratory tract where ACE2 receptors are not abundant, and the interaction with seasonal coronaviruses in older children [7]. Also, despite recent evidence that children have comparable viral loads with adults [8] and that infants and toddlers may spread SARS-CoV-2 [9], the current study findings support the notion that infants can rarely be a primary case and possibly not a source case for other members of their households either.

This study has some limitations. Firstly, this is a retrospective, single-centre study. However, it represents the general population, as the hospital is one of the two COVID-19 referral pediatric hospitals in Athens. Secondly, in this cohort, there were only three infants with severe COVID-19 disease and all infants were previously healthy with no co-morbidities. Finally, the study period reflects the hospitalizations during the first and second COVID-19 wave, but not the period when the delta and omicron variant were dominant.

We can safely suggest that infants with COVID-19 can be treated at their home environment since hospitalization can lead to unnecessary laboratory testing, parent-infant separation and increased risk for SARS-CoV-2 in-hospital transmission. It is of prime importance to determine the expected benefit of young child vaccination, and the number of adult cases prevented, especially when the vaccination coverage in other age groups is high. Studies on antibody kinetics and risk of reinfection from SARS-CoV-2 in this age group are under way and will further support decision-making.

**Ethics clearance:** Institutional ethics committee, ‘P. and A. Kyriakou’ Children’s Hospital, Athens, Greece; No.4336, dated 9 March, 2021.

**Contributors:** DD,MT,NS: conception and design of the work, acquisition and interpretation of data, drafting the manuscript; ML,IE: acquisition and interpretation of data for the work, revising it critically for important intellectual content. All authors approved the final version of the manuscript, and, agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Funding:** None; Competing interests: None stated.

**REFERENCES**

1. Götzinger F, Santiago-García B, Nogueira-Julián A, et al. COVID-19 in children and adolescents in Europe: A multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4:653-61.
2. Mark EG, Golden WC, Gilmore MM, et al. Community-onset severe acute respiratory syndrome coronavirus 2 infection in young infants: A systematic review. J Pediatr. 2021;228:94-100.e3.
3. Raba AA, Abobaker A, Elgeneidi IS, et al. Novel coronavirus infection (COVID-19) in children younger than one year: A systematic review of symptoms, management and outcomes. Acta Paediatr. 2020;109:1948-55.
4. Bellini T, Rotulo GA, Caraggi S, et al. Characteristics of COVID-19 patients up to 6 months of age admitted to a paediatric emergency department. Acta Pediatr. 2021;10.1111/apa.16166.
5. Public Health England (PHE). Understanding cycle threshold (Ct) in SARS-CoV-2 RT-PCR. A guide for health protection teams. October 2020. Accessed Dec 17, 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/926410/Understanding_Cycle_Threshold___Ct___in___SARS-CoV-2___RT-PCR_.pdf
6. National Institutes of Health (NIH). Clinical Spectrum of SARS-CoV-2 Infection. Last Updated: October 19, 2021. Accessed Dec 17, 2021. Available from: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/
7. Ladvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109:1088-95.
8. Madera S, Crawford E, Langelier C, et al. Nasopharyngeal SARS-CoV-2 viral loads in young children do not differ significantly from those in older children and adults. Sci Rep. 2021.
9. Paul LA, Daneman N, Schwartz KL, et al. Association of age and pediatric household transmission of SARS-CoV-2 infection. JAMA Pediatr. 2021;175:1515-58.